Brain and colleagues have shown that the addition of adjuvant chemotherapy to endocrine therapy does not result in a statistically significant overall survival (OS) benefit in patients older than 70 years with estrogen receptor (ER)-positive, Her2-negative breast cancer with a high tumor genomic grade index. This evidence concerns the gene ESR1 and breast cancer.